Genocea Biosciences Inc


Genocea Up 5% On FDA Nod For Cancer Therapy Application; Street Sees 353% Upside

Genocea Biosciences announced that the US Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for its GEN-011 cancer immunotherapy, …

A New Bull Sees 385% Upside for Genocea Biosciences Inc (NASDAQ:GNCA)

Genocea Biosciences Inc (NASDAQ:GNCA) shares are shooting up 25% faster than Jack’s magic bean sparking right into a giant beanstalk. The reason?

Genocea Biosciences Inc (GNCA) Shares Gain 17% in After Hours Trading – Here’s Why

Shares of Genocea Biosciences Inc (NASDAQ:GNCA) rose nearly 17% in after-hours trading Monday after analysts at Cantor started covering the stock, rating it …

No Love Lost Between Hedge Fund Guru James “Jim” Flynn and Valeant Pharmaceuticals Intl Inc (VRX), Genocea Biosciences Inc (GNCA); MannKind Corporation (MNKD) Is a Different Story

James “Jim” Flynn first walked onto the Deerfield Management team seventeen years ago, since a firm that cares about strides in the healthcare …

Should You Give up on Genocea Biosciences Inc (GNCA), Axovant Sciences Ltd (AXON)? Analysts Dive In

A tale of two beaten biotech stocks: GNCA, AXON.

Is It Time to Panic About Axovant Sciences Ltd (AXON) and Genocea Biosciences Inc (GNCA)? Analysts Weigh in

Healthcare analysts share two cents on two falling biotech stocks.

Genocea Biosciences Inc (GNCA) Investors Run for the Hills; Here’s Why

Genocea shares are plunging on termination of genital herpes treatment GEN-003.

Genocea Biosciences Inc (GNCA) May Be Crashing, But Here’s Why Cowen Sees A Significantly Undervalued Stock

Genocea Biosciences Inc (NASDAQ:GNCA) shares were plummeting almost 15% yesterday after the biotech firm and are another 5% dive today after a lackluster …

Cowen Sings the Praises of Genocea Biosciences Inc (GNCA) Following Positive GEN-003 Phase 2b Data

Cowen analyst Phil Nadeau is out with a bullish note on shares of Genocea Biosciences Inc (NASDAQ:GNCA), reiterating an Outperform rating with a $40 price …

Genocea Biosciences Inc (GNCA): This Analyst Turns Bullish, Sets $12 Target Price

In a research report issued Monday, Needham analyst Alan Carr upgraded shares of Genocea Biosciences Inc (NASDAQ:GNCA), while setting a new price target of $12.00, which …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts